Compare BAC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAC | AZN |
|---|---|---|
| Founded | 1784 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.6B | 316.4B |
| IPO Year | 2025 | 1995 |
| Metric | BAC | AZN |
|---|---|---|
| Price | $64.49 | $156.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $60.34 | N/A |
| AVG Volume (30 Days) | ★ 28.9M | 3.7M |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.12% | 1.73% |
| EPS Growth | ★ 18.69 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $113,097,000,000.00 | N/A |
| Revenue This Year | $13.11 | $10.34 |
| Revenue Next Year | $5.80 | $6.43 |
| P/E Ratio | ★ $27.75 | $31.91 |
| Revenue Growth | ★ 11.00 | N/A |
| 52 Week Low | $46.12 | $72.90 |
| 52 Week High | $65.20 | $212.71 |
| Indicator | BAC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 68.60 | 34.17 |
| Support Level | $51.20 | $153.41 |
| Resistance Level | N/A | $209.98 |
| Average True Range (ATR) | 0.97 | 2.90 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 83.71 | 12.59 |
Bank of America is a formidable financial titan with a $3.5 trillion balance sheet and a cornerstone of the American economy, holding the second-largest deposit market share in the United States. While the firm has maintained its stronghold among middle-market and retail clientele domestically, Bank of America has continued to hold its own on the global stage, as evidenced by its fourth-largest global trading operation and an investment banking division that regularly finishes in the top four in global league tables. The firm is organized across four segments: consumer banking, global wealth and investment management, global banking, and global markets.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.